Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 15

1145P - Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: The ComIT-1 trial

Date

10 Sep 2022

Session

Poster session 15

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Henrik Horndalsveen

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

H. Horndalsveen1, T.N. Alver2, A.M. Dalsgaard2, Å.K. Öjlert1, V.D. Haakensen1, M.M. Bjaanaes3, A. Helland4

Author affiliations

  • 1 Department Of Oncology And Department Of Cancer Genetics, Oslo University Hospital, 0424 - Oslo/NO
  • 2 Department Of Cancer Genetics, Oslo University Hospital, 0424 - Oslo/NO
  • 3 Department Of Oncology, Oslo University Hospital - Ulleval Hospital, 0424 - Oslo/NO
  • 4 Oncology Dept., University of Oslo, Institute of Clinical medicine, 310 - Oslo/NO

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1145P

Background

The emerging use of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer (NSCLC). However, challenges remain to increase the number of patients achieving durable clinical responses to these drugs, and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumor DNA (ctDNA) responses in patients with advanced NSCLC treated with atezolizumab and stereotactic body radiotherapy (SBRT).

Methods

Patients with metastatic NSCLC previously treated with a platinum doublet were included. SBRT (3 doses of 6 Gy) was given with concurrent atezolizumab 1200 mg every three weeks until no clinical benefit, intolerable toxicity, or a maximum of two years. Safety and clinical responses were registered. Plasma collected at baseline, during treatment and at progression was analyzed by next-generation sequencing using a 52-gene panel. We examined the relationship between longitudinal changes in ctDNA levels quantified using the allele frequency (AF) of lung cancer-associated somatic mutations, and radiographic responses for each patient.

Results

21 patients were enrolled, of whom 15 with programmed death-ligand 1 (PD-L1) negative tumors. Grade 3 treatment-related adverse events were reported in three patients, leading to permanent discontinuation of treatment in one. No patients experienced grade 4–5 toxicity. Median overall survival time was still not reached at data cut-off. As best overall response, four patients had a partial response (PR), eight had stable disease (SD) and five had progressive disease (PD). Eight patients, including six with PD-L1 negative tumors, were on treatment for more than 12 months. ctDNA was detectable at baseline in 11 plasma samples. A rapid decline in ctDNA to <30% of baseline levels was seen for three patients, two of them radiographic responders and one considered clinically benefiting from therapy for almost one year.

Conclusions

Atezolizumab was safely administered concomitant with SBRT, but further trials are needed to assess the efficacy of this combination. ctDNA holds potential as a dynamic biomarker in lung cancer patients receiving immune checkpoint inhibitors.

Clinical trial identification

EudraCT: 2017-003562-27; NCT03644823.

Editorial acknowledgement

Legal entity responsible for the study

Oslo University Hospital Oslo University Hospital.

Funding

The Norwegian Cancer Society, the South-Eastern Norway Regional Health Authority, Roche.

Disclosure

H. Horndalsveen: Financial Interests, Advisory Board: Janssen; Financial Interests, Invited Speaker: AstraZeneca, Pfizer, Roche. V.D. Haakensen: Financial Interests, Advisory Board: Novartis, AstraZeneca, Pfizer; Financial Interests, Invited Speaker: BMS, AstraZeneca, Takeda. A. Helland: Financial Interests, Institutional, Advisory Board, Advisory boards: Jansen, Takeda, AstraZeneca, AbbVie, Roche, BMS, Pfizer, MSD, Bayer, Lilly; Financial Interests, Institutional, Invited Speaker, talks at meetings: AstraZeneca, Roche, AbbVie, Pfizer; Financial Interests, Institutional, Invited Speaker, BMS provides drug to patients in an investigator initiated clinical trial: BMS; Financial Interests, Institutional, Invited Speaker, provides drug and funds for investigator initiated clinical trial: Ultimovacs, AstraZeneca, Roche; Financial Interests, Institutional, Invited Speaker, provides drug and funds for clinical trial: Novartis, Eli Lilly, Incyte; Non-Financial Interests, Other, Board member in the patient organisation. Provides advice and gives talks: The lung cancer patients organisation. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.